Impax Announces Sale of Daraprim® to Turing Pharmaceuticals AG
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
Go back to Impax Announces Sale of Daraprim® to Turing Pharmaceuticals AG
August 11, 2015 9:05 AM EDT
Leerink Partners maintained a Market Perform rating on Impax Laboratories (NASDAQ: IPXL), and cut the price target to $47.00 (from $49.00), following its 2Q15 earnings report. IPXL reported revenue of $214m compared to the Street's $200m estimate. IPXL lowered its 2015 GM guidance, now in the low 50s (vs.... More
August 10, 2015 6:46 AM EDT
Impax Laboratories (NASDAQ: IPXL) reported Q2 EPS of $0.34, $0.01 worse than the analyst estimate of $0.35. Revenue for the quarter came in at $214.2 million versus the consensus estimate of $199.93 million.
For earnings history and earnings-related data on Impax Laboratories (IPXL) click here.
...
More
August 10, 2015 6:31 AM EDT
Impax Laboratories (NASDAQ: IPXL) announced that it has sold its U.S. rights to the Daraprim brand to Turing Pharmaceuticals AG for approximately $55 million.
Impax acquired Daraprim as part of the Company's acquisition of Tower Holdings, Inc. (including operating subsidiaries CorePharma LLC and Amedra... More
